Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Absenger Gudrun |
** = Publikationen gelistet in SCI/SSCI/Pubmed
2022
Originalarbeit (Zeitschrift)
** Barth, DA; Stanzer, S; Spiegelberg, J; Bauernhofer, T; Absenger, G; Posch, F; Lipp, R; Halm, M; Szkandera, J; Balic, M; Gerger, A; Smolle, MA; Hutterer, GC; Klec, C; Jost, PJ; Kargl, J; Stradner, M; Pichler, M
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Cancer Med. 2022; 11(16):3074-3083
Doi: 10.1002/cam4.4675
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207
Doi: 10.3389/fimmu.2022.840207
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Illini, O; Fabikan, H; Hochmair, MJ; Weinlinger, C; Krenbek, D; Brcic, L; Setinek, U; Terbuch, A; Absenger, G; Konjić, S; Valipour, A
Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study.
J Clin Med. 2022; 11(14):
Doi: 10.3390/jcm11144098
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Kurzbericht/Letter
** Terbuch, A; Absenger, G
Neoadjuvant treatment in non-small-cell lung cancer-the earlier, the better
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00828-3
Web of Science
FullText
FullText_MUG
Abstract (Zeitschrift)
** Brcic, L; Zacharias, M; Konjic, S; Kashofer, K; Absenger, G; Jost, PJ; Wurm, R; Lindenmann, J; Terbuch, A
Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A singlecenter experience
ANN ONCOL. 2022; 38(9): S1557-S1557.
Doi: 10.1016/j.annonc.2022.10.344
[Poster]
Web of Science
FullText
FullText_MUG
** Hochmair, M; Absenger, G; Ay, L; Robinson, I; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipou, A
Introducing "BiomeOne" a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients
J THORAC ONCOL. 2022; 17(9): S561-S561.
[Poster]
Web of Science
** Hochmair, M; Schmidinger, M; Ay, L; Robinson, I; Absenger, G; Pichler, M; Nguyen, VA; Richtig, E; Rainer, B; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipour, A
BiomeOne: multi-center Validation of a new microbiome-based Biomarker to predict Response to Cancer Immunotherapy
ONCOL RES TREAT. 2022; 45(SUPPL 2):229-229.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
** Illini, O; Fabikan, H; Hochmair, MJ; Weinlinger, C; Krenbek, D; Brcic, L; Setinek, U; Terbuch, A; Absenger, G; Konji, S; Valipour, A
Characteristics and treatment outcomes in advanced stage non-small cell lung cancer patients with KRAS G12C mutation
WIEN KLIN WOCHENSCHR. 2022; 134(19-20):727-728.
Web of Science
** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
** Robinson, I; Hochmair, MJ; Jansen, C; Pacifico, C; Sladek, B; Knabl, A; Gasche, N; Absenger, G; Pichler, M; Valipour, A
Prediction of immune checkpoint inhibitor (ICI) response in non-small cell lung cancer (NSCLC) patients using a microbiome-based biomarker
WIEN KLIN WOCHENSCHR. 2022; 134(19-20): 742-742.
[Poster]
Web of Science
** Robinson, I; Schmidinger, M; Hochmair, MJ; Ay, L; Absenger, G; Pichler, M; Nguyen, VAF; Richtig, E; Rainer, B; Jansen, C; Sladek, B; Knabl, A; Gasche, N; Valipour, A
BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy
ANN ONCOL. 2022; 33(7):S592-S592.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); SEP 09-13, 2022; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2022.07.149
[Poster]
Web of Science
FullText
FullText_MUG
** Zacharias, M; Konjic, S; Absenger, G; Hochmair, MJ; Fabikan, H; Weinlinger, C; Illini, O; Jost, PJ; Schlintl, V; Wurm, R; Lindenmann, J; Fediuk, M; Brcic, L; Terbuch, A
Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
J THORAC ONCOL. 2022; 17(9): S201-S202.
[Poster]
Web of Science
2021
Originalarbeit (Zeitschrift)
** Chapel, DB; Schulte, JJ; Absenger, G; Attanoos, R; Brcic, L; Butnor, KJ; Chirieac, L; Churg, A; Galateau-Sallé, F; Hiroshima, K; Hung, YP; Kindler, H; Krausz, T; Marchevsky, A; Mino-Kenudson, M; Mueller, J; Nabeshima, K; Turaga, K; Walts, AE; Husain, AN
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.
Mod Pathol. 2021; 34(2):380-395
Doi: 10.1038/s41379-020-00688-4
Web of Science
PubMed
FullText
FullText_MUG
** Geiger-Gritsch, S; Olschewski, H; Kocher, F; Wurm, R; Absenger, G; Flicker, M; Hermann, A; Heininger, P; Fiegl, M; Zechmeister, M; Endel, F; Wild, C; Pall, G
Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study.
Wien Klin Wochenschr. 2021; 133(21-22):1122-1130
Doi: 10.1007/s00508-021-01940-w
Web of Science
PubMed
FullText
FullText_MUG
** Illini, O; Hochmair, MJ; Fabikan, H; Weinlinger, C; Tufman, A; Swalduz, A; Lamberg, K; Hashemi, SMS; Huemer, F; Vikstrom, A; Wermke, M; Absenger, G; Addeo, A; Banerji, S; Calles, A; Clarke, S; Di Maio, M; Durand, A; Duruisseaux, M; Itchins, M; Kaaranien, OS; Krenn, F; Laack, E; de Langen, AJ; Mohorcic, K; Pall, G; Passaro, A; Prager, G; Rittmeyer, A; Rothenstein, J; Schumacher, M; Woll, E; Valipour, A
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
THER ADV MED ONCOL. 2021; 13: 17588359211019675
Doi: 10.1177/17588359211019675
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Zacharias, M; Absenger, G; Kashofer, K; Wurm, R; Lindenmann, J; Terbuch, A; Konjic, S; Sauer, S; Gollowitsch, F; Gorkiewicz, G; Brcic, L
Reflex testing in non-small cell lung carcinoma using DNA-and RNA-based next-generation sequencing-a single-center experience
TRANSL LUNG CANCER R. 2021;
Doi: 10.21037/tlcr-21-570
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Absenger, G; Pircher, A
ASCO 2021-selection of personal highlights in early stage non-small cell lung cancer
MEMO-MAG EUR MED ONC. 2021;
Doi: 10.1007/s12254-021-00770-w
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Absenger, G; Terbuch, A
Unresectable pleural mesothelioma-hope or still an unmet medical need?
MEMO-MAG EUR MED ONC. 2021;
Doi: 10.1007/s12254-021-00727-z
Web of Science
FullText
FullText_MUG
** Kaiser, M; Semeraro, MD; Herrmann, M; Absenger, G; Gerger, A; Renner, W
Immune Aging and Immunotherapy in Cancer.
Int J Mol Sci. 2021; 22(13): 7016
Doi: 10.3390/ijms22137016
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Terbuch, A; Absenger, G; Steinlechner, S; Jost, P; Wurm, R; Wohlkonig, C; Olschewski, H; Richtig, E; Koch, L; Winder, T; Woll, E; Gerger, A
Autriche - AUsTrian Registry for Immune CHEckpoint inhibitors
ONCOL RES TREAT. 2021; 44: 229-229.
[Poster]
Web of Science
2020
Originalarbeit (Zeitschrift)
** Hochmair, MJ; Fabikan, H; Illini, O; Weinlinger, C; Setinek, U; Krenbek, D; Prosch, H; Rauter, M; Schumacher, M; Wöll, E; Wass, R; Brehm, E; Absenger, G; Bundalo, T; Errhalt, P; Urban, M; Valipour, A
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis.
PHARMACEUTICALS-BASE. 2020; 13(11):
Doi: 10.3390/ph13110371
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Popper, HH; Gruber-Mosenbacher, U; Pall, G; Mullauer, L; Hochmair, M; Krenbek, D; Brcic, L; Schmitz, K; Lamprecht, B; Eckmayr, J; Hilbe, W; Hutarew, G; Errhalt, P; Kolb, R; Pirker, R; Setinek, U; Webersinke, G; Absenger, G; Hernler, T; Rauter, M; Wasicky, R
The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers.
MEMO-MAG EUR MED ONC. 2020;
Doi: 10.1007/s12254-019-00565-0
Web of Science
FullText
FullText_MUG
** Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8):
Doi: 10.3390/cancers12082319
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Illini, O; Hochmair, MJ; Fabikan, H; Weinlinger, C; Setinek, U; Krenbek, D; Prosch, H; Rauter, M; Schumacher, M; Woll, E; Wass, R; Brehm, E; Absenger, G; Bundalo, T; Errhalt, P; Urban, M; Valipour, A
Later-line treatment with lorlatinib in ALK-and ROS1-rearrangement-positive NSCLC: a retrospective, multicenter analysis.
WIEN KLIN WOCHENSCHR. 2020; 132(19-20):610-610.
[Poster]
Web of Science
** Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM
C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.234
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
2019
Übersichtsarbeit
** Absenger, G
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance
MEMO-MAG EUR MED ONC. 2019; 12(2): 128-135.
Doi: 10.1007/s12254-019-0488-3
Web of Science
FullText
FullText_MUG
Abstract (Zeitschrift)
** Barth, DA; Riedl, JM; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 108-108.
[Poster]
Web of Science
** Dandachi, N; Absenger, G; Brcic, L; Kashofer, K; Terbuch, A; Jaritz, L; Stanzer, S; Balic, M
Feasibility and clinical value of serial circulating tumor DNA testing in metastatic lung adenocarcinoma patients undergoing TKI treatment
ONCOL RES TREAT. 2019; 42: 213-213.
[Poster]
Web of Science
** Hochmair, MJ; Weinlinger, C; Fabikan, H; Illini, O; Krenbek, D; Setinek, U; Watzka, S; Koger, R; Meilinger, M; Absenger, G; Wanke, M; Semmelweis, C; Rauter, M; Valipour, A
Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROS1 Rearranged NSCLC Patients
J THORAC ONCOL. 2019; 14(10):S847-S847.
Doi: 10.1016/j.jtho.2019.08.1831
[Poster]
Web of Science
FullText
FullText_MUG
** Riedl, JM; Barth, D; Posch, F; Foris, V; Absenger, G; Mollnar, S; Pichler, M; Stotz, M; Stoger, H; Olschewski, H; Gerger, A
Longitudinal C-reactive protein (CRP) trajectories predict immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 115-115.
[Poster]
Web of Science
** Riedl, JM; Barth, DA; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
ANN ONCOL. 2019; 30: -44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN.
[Poster]
Web of Science
2018
Originalarbeit (Zeitschrift)
** Brcic, L; Stanzer, S; Krenbek, D; Gruber-Moesenbacher, U; Absenger, G; Quehenberger, F; Valipour, A; Lindenmann, J; Stoeger, H; Al Effah, M; Fediuk, M; Balic, M; Popper, HH
Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung.
Virchows Arch. 2018; 472(4):589-598
Doi: 10.1007/s00428-018-2326-0
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Buder, A; Hochmair, MJ; Schwab, S; Bundalo, T; Schenk, P; Errhalt, P; Mikes, RE; Absenger, G; Patocka, K; Baumgartner, B; Setinek, U; Burghuber, OC; Prosch, H; Pirker, R; Filipits, M
Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
J Thorac Oncol. 2018; 13(6):821-830
Doi: 10.1016/j.jtho.2018.02.014
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2017
Originalarbeit (Zeitschrift)
** Dandachi, N; Tiran, V; Lindenmann, J; Brcic, L; Fink-Neuboeck, N; Kashofer, K; Absenger, G; Bezan, A; Cote, RJ; Datar, R; Balic, M
Frequency and clinical impact of preoperative circulating tumor cells in resectable non-metastatic lung adenocarcinomas.
Lung Cancer. 2017; 113(46):152-157
Doi: 10.1016/j.lungcan.2017.10.003
Web of Science
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Absenger, G; Terzic, J; Bezan, A
ASCO update: lung cancer.
Memo. 2017; 10(4):224-227
Doi: 10.1007/s12254-017-0373-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Hochmair, M; Holzer, S; Filipits, M; Mohn-Staudner, A; Errhalt, P; Absenger, G; Bundalo, T; Arns, M; Setinek, U; Mikes, R; Kolb, R; Schumacher, M; Zochbauer-Muller, S; Patocka, K; Haslbauer, F; Rudzki, J; Burghuber, O
EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
J THORAC ONCOL. .. 2017; 12(1):S1254-S1254.
Doi: 10.1016/j.jtho.2016.11.1769
[Poster]
Web of Science
FullText
FullText_MUG
2016
Originalarbeit (Zeitschrift)
** Popper, HH; Gruber-Mosenbacher, U; Hutarew, G; Hochmair, M; Absenger, G; Brcic, L; Mullauer, L; Dekan, G; Setinek, U; Krenbek, D; Vesely, M; Pirker, R; Hilbe, W; Kolb, R; Webersinke, G; Hernler, T; Pall, G; Lax, S; Mohn-Staudner, A
Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer
MEMO-MAG EUR MED ONC. 2016; 9(4): 191-200.
Doi: 10.1007/s12254-016-0297-x
Web of Science
FullText
FullText_MUG
Abstract (Zeitschrift)
** Holzer, S; Hochmair, M; Filipits, M; Mohn-Staudner, A; Errhalt, P; Absenger, G; Bundalo, T; Arns, BM; Setinek, U; Mikes, R; Kolb, R; Schumacher, M; Zochbauer-Muller, S; Patocka, K; Haslbauer, F; Rudzki, J; Burghuber, OC
EGFR T790M resistance mutation in NSCLC: Real-life data of Austrian patients treated with osimertinib
WIEN KLIN WOCHENSCHR. 2016; 128(19-20):769-770.
[Poster]
Web of Science
2014
Originalarbeit (Zeitschrift)
** Absenger, G; Benhaim, L; Szkandera, J; Zhang, W; Yang, D; Labonte, MJ; Pichler, M; Stotz, M; Samonigg, H; Renner, W; Gerger, A; Lenz, HJ
The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.
Pharmacogenomics J. 2014; 14(2):130-134
Doi: 10.1038/tpj.2013.15
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
** Stotz, M; Pichler, M; Absenger, G; Szkandera, J; Arminger, F; Schaberl-Moser, R; Samonigg, H; Stojakovic, T; Gerger, A
The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.
Br J Cancer. 2014; 110(2):435-440
Doi: 10.1038/bjc.2013.785
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Gerger, A; Liegl-Atzwanger, B; Absenger, G; Stotz, M; Friesenbichler, J; Trajanoski, S; Stojakovic, T; Eberhard, K; Leithner, A; Pichler, M
The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas.
Int J Cancer. 2014; 135(2):362-370
Doi: 10.1002/ijc.28677
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Pichler, M; Absenger, G; Stotz, M; Arminger, F; Weissmueller, M; Schaberl-Moser, R; Samonigg, H; Kornprat, P; Stojakovic, T; Avian, A; Gerger, A
The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients.
Am J Surg. 2014; 208(2):210-214
Doi: 10.1016/j.amjsurg.2013.10.030
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Pichler, M; Absenger, G; Stotz, M; Weissmueller, M; Samonigg, H; Asslaber, M; Lax, S; Leitner, G; Winder, T; Renner, W; Gerger, A
A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.
Clin Cancer Res. 2014; 20(6):1687-1697
Doi: 10.1158/1078-0432.CCR-13-1517
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Pichler, M; Liegl-Atzwanger, B; Absenger, G; Stotz, M; Ploner, F; Stojakovic, T; Samonigg, H; Eberhard, K; Leithner, A; Gerger, A
The elevated pre-operative plasma fibrinogen level is an independent negative prognostic factor for cancer-specific, disease-free and overall survival in soft-tissue sarcoma patients.
J Surg Oncol. 2014; 109(2):139-144
Doi: 10.1002/jso.23458
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Stotz, M; Absenger, G; Stojakovic, T; Samonigg, H; Kornprat, P; Schaberl-Moser, R; Alzoughbi, W; Lackner, C; Ress, AL; Seggewies, FS; Gerger, A; Hoefler, G; Pichler, M
Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.
Br J Cancer. 2014; 110(1):183-188
Doi: 10.1038/bjc.2013.701
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2013
Originalarbeit (Zeitschrift)
** Absenger, G; Szkandera, J; Pichler, M; Stotz, M; Arminger, F; Weissmueller, M; Schaberl-Moser, R; Samonigg, H; Stojakovic, T; Gerger, A
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients.
Br J Cancer. 2013; 109(2):395-400
Doi: 10.1038/bjc.2013.346
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Absenger, G; Szkandera, J; Stotz, M; Pichler, M; Winder, T; Langsenlehner, T; Langsenlehner, U; Samonigg, H; Renner, W; Gerger, A
A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer.
Mol Carcinog. 2013; 52 Suppl 1(9):E96-102
Doi: 10.1002/mc.22028
Web of Science
PubMed
FullText
FullText_MUG
** Absenger, G; Szkandera, J; Stotz, M; Postlmayr, U; Pichler, M; Ress, AL; Schaberl-Moser, R; Loibner, H; Samonigg, H; Gerger, A
Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer.
Anticancer Res. 2013; 33(10):4591-4594
Web of Science
PubMed
** Stotz, M; Eisner, F; Szkandera, J; Absenger, G; Kornprat, P; Lackner, C; Samonigg, H; Gerger, A; Pichler, M
Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
J Clin Pathol. 2013; 66(9):753-757
Doi: 10.1136/jclinpath-2012-201394
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Absenger, G; Liegl-Atzwanger, B; Pichler, M; Stotz, M; Gerger, S; Zacherl, M; Renner, W; Haijun, M; Leithner, A; Gerger, A
Common gene variants in RAD51, XRCC2 and XPD are not associated with clinical outcome in soft-tissue sarcoma patients.
Cancer Epidemiol. 2013; 37(6):1003-1009
Doi: 10.1016/j.canep.2013.10.003
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Absenger, G; Liegl-Atzwanger, B; Pichler, M; Stotz, M; Samonigg, H; Glehr, M; Zacherl, M; Stojakovic, T; Gerger, A; Leithner, A
Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients.
Br J Cancer. 2013; 108(8):1677-1683
Doi: 10.1038/bjc.2013.135
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Absenger, G; Pichler, M; Stotz, M; Langsenlehner, T; Samonigg, H; Renner, W; Gerger, A
Association of common gene variants in vitamin D modulating genes and colon cancer recurrence.
J Cancer Res Clin Oncol. 2013; 139(9):1457-1464
Doi: 10.1007/s00432-013-1461-x
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Gerger, A; Liegl-Atzwanger, B; Absenger, G; Stotz, M; Samonigg, H; Maurer-Ertl, W; Stojakovic, T; Ploner, F; Leithner, A; Pichler, M
Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients.
Br J Cancer. 2013; 109(9):2316-2322
Doi: 10.1038/bjc.2013.595
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Stotz, M; Eisner, F; Absenger, G; Stojakovic, T; Samonigg, H; Kornprat, P; Schaberl-Moser, R; Alzoughbi, W; Ress, AL; Seggewies, FS; Gerger, A; Hoefler, G; Pichler, M
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.
PLoS One. 2013; 8(11):e78225-e78225
Doi: 10.1371/journal.pone.0078225
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Winder, T; Stotz, M; Weissmueller, M; Langsenlehner, T; Pichler, M; Samonigg, H; Renner, W; Gerger, A; Absenger, G
A common gene variant in PLS3 predicts colon cancer recurrence in women.
Tumour Biol. 2013; 34(4):2183-2188
Doi: 10.1007/s13277-013-0754-7
Web of Science
PubMed
FullText
FullText_MUG
2012
Originalarbeit (Zeitschrift)
** Szkandera, J; Absenger, G; Dandachi, N; Regitnig, P; Lax, S; Stotz, M; Samonigg, H; Renner, W; Gerger, A
Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Mol Genet Genomics. 2012; 287(9):755-764
Doi: 10.1007/s00438-012-0715-7
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Absenger, G; Stotz, M; Weissmueller, M; Winder, T; Langsenlehner, T; Samonigg, H; Renner, W; Schippinger, W; Gerger, A
The Functional Polymorphism of Erythropoietin Gene rs1617640 G>T Is Not Associated with Susceptibility and Clinical Outcome of Early-stage Breast Cancer.
Anticancer Res. 2012; 32(8):3473-3478
Web of Science
PubMed
Abstract (Zeitschrift)
** Absenger, G; Szkandera, J; Weissmuller, M; Postlmayr, U; Pichler, M; Loibner, H; Samonigg, HS; Gerger, A;
The preoperative neutrophil to lymphocyte ratio predicts disease-free survival and overall survival in patients with stage II and III colon cancer.
ONKOLOGIE. ONKOLOGIE35: 55-56. BASEL: KARGER;
[Poster]
Web of Science
** Hofmann, G; Langsenlehner, T; Moazedi-Fuerst, F; Gerger, A; Kielhauser, S; Absenger, G; Szkandera, J; Samonigg, H; Krippl, P; Renner, W;
COMMON VEGF GENE POLYMORPHISMS ARE NOT ASSOCIATED WITH RELAPSE-FREE SURVIVAL IN COLORECTAL CANCER PATIENTS.
ANN ONCOL. 2012; 23: 86-87.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN.
[Poster]
Web of Science
** Hofmann, G; Langsenlehner, T; Moazedi-Fuerst, F; Gerger, A; Kielhauser, S; Thurner, E-M; Absenger, G; Szkandera, J; Samonigg, H; Glehr, M; Krippl, P; Renner, W
Genetic variants of UGT1A4 and their impact on relapse-free survival in Tamoxifen treated breast cancer patients.
Onkologie. 2012; 35(S 6):64-64.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OCT 19-23, 2012; Stuttgart, GERMANY.
[Poster]
Web of Science
** Krenn-Pilko, S; Thurner, EM; Absenger, G; Renner, W; Gerger, A; Kapp, KS; Langsenlehner, U; Langsenlehner, T;
Association Between Variants in the VEGF Gene and Distant Metastases in Postmenopausal Breast Cancer Patients.
EUR J CANCER. EUROPEAN JOURNAL OF CANCER48: S271-S271. OXFORD: ELSEVIER SCI LTD; ( Presented at: 22nd Biennial Congress of the European-Association-for-Cancer-Research, Barcelona, SPAIN, JUL 07-10, 2012)
Doi: 10.1016/S0959-8049(12)71726-4
[Poster]
Web of Science
FullText
FullText_MUG
** Krenn-Pilko, S; Thurner, EM; Renner, W; Absenger, G; Gerger, A; Kapp, KS; Langsenlehner, T; Langsenlehner, U
The Development of Distant Metastases in Postmenopausal Woman with Breast Cancer in Association with VEGF Gene Polymorphisms
EUR J CANCER. 2012; 48: 63-63.-24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; NOV 06-09, 2012; Dublin, IRELAND.
Doi: 10.1016/S0959-8049(12)72008-7
[Poster]
Web of Science
FullText
FullText_MUG
** Szkandera, J; Absenger, G; Dandachi, N; Regitnig, P; Lax, S; Stotz, M; Winder, T; Samonigg, H; Renner, W; Gerger, A
Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer
WIEN KLIN WOCHENSCHR. 2012; 124(15-16):575-575.
[Poster]
Web of Science
** Szkandera, J; Absenger, G; Stotz, M; Weissmuller, M; Winder, T; Langsenlehner, T; Samonigg, H; Renner, W; Schippinger, W; Gerger, A
The functional polymorphism of erythropoietin gene rs1617640 G > T is not associated with susceptibility and clinical outcome of early-stage breast cancer
WIEN KLIN WOCHENSCHR. 2012; 124(15-16):575-575.
[Poster]
Web of Science
** Szkandera, J; Winder, T; Absenger, G; Stotz, M; Weissmuller, M; Langsenlehner, T; Hofmann, G; Samonigg, H; Renner, W; Gerger, A;
A COMMON GENE VARIANT IN PLS3 PREDICTS COLON CANCER RECURRENCE IN WOMEN.
ANN ONCOL. 2012; 23: 83-83.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN.
[Poster]
Web of Science
Abstract (Konferenzband)
** Thurner, EM; Krenn-Pilko, S; Absenger, G; Hofmann, G; Gerger, A; Langsenlehner, U; Kapp, KS; Langsenlehner, T
Correlations between variants in the ERCC2 gene and the risk of the development of radiation induced late toxicity in prostate cancer patients
Onkologie - International Journal for Cancer Research and Treatment. 2012; 35(6):182-182.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaft für Hämatologie und Onkologie; OKT 19-23, 2012; Stuttgart, GERMANY. (ISBN: 978-3-318-02304-6 )
[Oral Communication]
Web of Science
2011
Originalarbeit (Zeitschrift)
** Gerger, A; El-Khoueiry, A; Zhang, W; Yang, D; Singh, H; Bohanes, P; Ning, Y; Winder, T; Labonte, MJ; Wilson, PM; Benhaim, L; Paez, D; El-Khoueiry, R; Absenger, G; Lenz, HJ
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Clin Cancer Res. 2011; 17(17):5783-5792
Doi: 10.1158/1078-0432.CCR-11-1115
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Hofmann, G; Langsenlehner, U; Langsenlehner, T; Glehr, M; Gerger, A; Absenger, G; Szkandera, J; Fuerst, F; Samonigg, H; Krippl, P; Renner, W
Single nucleotide polymorphisms of integrin alpha-2 and beta-3 genes are not associated with relapse-free and overall survival in colorectal cancer patients.
Anticancer Res. 2011; 31(4):1373-1377
Web of Science
PubMed
Abstract (Zeitschrift)
** Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Bitsche, S; Absenger, G; Samonigg, H; Krippl, P; Renner, W
RELAPSE-FREE SURVIVAL IN COLORECTAL CANCER PATIENTS IS NOT ASSOCIATED WITH SINGLE NUCLEOTIDE POLYMORPHISMS IN INTEGRIN RECEPTOR SUBUNITS
ANN ONCOL. 2011; 22: v109-v109.-ESMO 13th World Congress on Gastrointestinal Cancer ; JUN 22-25, 2011; Barcelona, SPAIN.
[Poster]
Web of Science
** Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Szkandera, J; Absenger, G; Samonigg, H; Krippl, P; Renner, W
A COMMON HEREDITARY SINGLE NUCLEOTIDE POLYMORPHISM IN THE IN THE GENE OF DEATH RECEPTOR 4 (TNFRSF10A) AND ITS IMPACT ON OVERALL SURVIVAL IN RECTAL CANCER PATIENTS
ANN ONCOL. . 2011; 22: v129-v129.-ESMO 13th World Congress on Gastrointestinal Cancer; JUN 22-25, 2011; Barcelona, SPAIN.
[Poster]
Web of Science
** Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Szkandera, J; Absenger, G; Samonigg, H; Krippl, P; Renner, W
Common single nucleotide polymorphisms in the genes of integrin alpha-2 and beta-3 subunits are not associated with overall survival in rectal cancer patients
ONKOLOGIE. 2011; 34: 245-246.-Gemeinsame Jahrestagung 2011 der DGHO, ÖGHO, SGMO und SGH+SSH; SEP 30-OCT 4, 2011; Basel, SWITZERLAND.
[Poster]
Web of Science
2010
Originalarbeit (Zeitschrift)
** Gerger, A; Renner, W; Langsenlehner, T; Hofmann, G; Knechtel, G; Szkandera, J; Samonigg, H; Krippl, P; Langsenlehner, U
Association of interleukin-10 gene variation with breast cancer prognosis.
Breast Cancer Res Treat. 2010; 119(3):701-705
Doi: 10.1007/s10549-009-0417-y
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
** Knechtel, G; Hofmann, G; Gerger, A; Renner, W; Langsenlehner, T; Szkandera, J; Wolf, G; Samonigg, H; Krippl, P; Langsenlehner, U
Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.
J Cancer Res Clin Oncol. 2010; 136(12):1813-1819
Doi: 10.1007/s00432-010-0839-2
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
** Knechtel, G; Stoeger, H; Szkandera, J; Dorr, K; Beham, A; Samonigg, H
Desmoid tumor treated with polychemotherapy followed by imatinib: a case report and review of the literature.
Case Rep Oncol. 2010; 3(2): 287-293.
Doi: 10.1159/000318873
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
** Knechtel, G; Szkandera, J; Stotz, M; Hofmann, G; Langsenlehner, U; Krippl, P; Samonigg, H; Renner, W; Langner, C; Dehchamani, D; Gerger, A
Single nucleotide polymorphisms in the hypoxia-inducible factor-1 gene and colorectal cancer risk.
Mol Carcinog. 2010; 49(9):805-809
Doi: 10.1002/mc.20655
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Knechtel, G; Stotz, M; Hofmann, G; Langsenlehner, U; Krippl, P; Langsenlehner, T; Dehchamani, D; Samonigg, H; Renner, W; Gerger, A
Association of hypoxia-inducible factor 1-alpha gene polymorphisms and colorectal cancer prognosis.
Anticancer Res. 2010; 30(6):2393-2397
Web of Science
PubMed
Google Scholar
** Szkandera, J; Ploner, F; Bauernhofer, T; Kasparek, AK; Payer, F; Balic, M; Knechtel, G; Gerger, A; Gallè, G; Samonigg, H; Hofmann, G
Paraneoplastic limbic encephalitis in a patient with extragonadal choriocarcinoma--significance of onconeural antibodies.
Onkologie. 2010; 33(8-9):452-454
Doi: 10.1159/000317269
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Knechtel, G; Samonigg, H; Krippl, P; Renner, W
COMMON VEGF RECEPTOR GENE POLYMORPHISMS AND THEIR INFLUENCE ON OVERALL SURVIVAL IN COLORECTAL CANCER PATIENTS
Annals of Oncology2010; 21(S 6):35-35.-12th World Congress on Gastrointestinal Cancer; June 30-July 3, 2010; Barcelona, SPAIN.
[Poster]
Web of Science
** Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Knechtel, G; Samonigg, H; Krippl, P; Renner, W
ASSOCIATION OF COMMON SINGLE NUCLEOTIDE POLYMORPHISMS IN INTEGRINS WITH METASTASIS-FREE SURVIVAL IN RECTAL CANCER PATIENTS
Annals of Oncology2010; 21(S 6):59-59.-12th World Congress on Gastrointestinal Cancer; June 30-July 3, 2010; Barcelona, SPAIN.
[Poster]
Web of Science
** Knechtel, G; Szkandera, J; Stotz, M; Hofmann, G; Langsenlehner, U; Krippl, P; Samonigg, H; Renner, W; Dehchamani, D; Gerger, A
Single nucleotide polymorphisms in the hypoxia-inducible factor 1 gene and colorectal cancer risk
Onkologie-International Journal for Cancer Research and Treatment2010; 33(S6):225-226.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OKT 1-5, 2010; Berlin, GERMANY. (ISBN: 978-3-8055-9633-6 )
[Oral Communication]
Web of Science
** Szkandera, J; Knechtel, G; Stotz, M; Hofmann, G; Langsenlehner, U; Krippl, P; Langsenlehner, T; Dehchamani, D; Samonigg, H; Renner, W; Gerger, A
Association of Hypoxia Inducible Factor 1-alpha Gene Polymorphisms and Colorectal Cancer Prognosis.
Onkologie-International Journal for Cancer Research and Treatment2010; 33(S6):226-226.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OKT 1-5, 2010; Berlin, GERMANY. (ISBN: 978-3-8055-9633-6 )
[Oral Communication]
Web of Science
2009
Abstract (Zeitschrift)
** Hofmann, G; Langsenlehner, T; Fuerst, F; Gerger, A; Langsenlehner, U; Knechtel, G; Szkandera, J; Krippl, P; Renner, W
The 683A>C polymorphism in the ligand binding domain of TRAILR-1 (TNFRSF10A) is not associated with colorectal cancer survival.
Annals of Oncology2009; 20(S 7):31-31.-11th World Congress on Gastrointestinal Cancer ; JUNE 24-27, 2009; Barcelona, SPAIN.
[Poster]
Web of Science